Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

27.00
+0.30111.13%
Post-market: 27.000.00000.00%16:10 EDT
Volume:392
Turnover:10.60K
Market Cap:5.40M
PE:- -
High:27.00
Open:27.00
Low:27.00
Close:26.70
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:0.61
T/O Rate:0.20%
Dividend:0.41
Dividend Rate:1.53%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk

Dow Jones
·
Aug 24

Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851

TIPRANKS
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Simply Wall St.
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

Hims & Hers (HIMS) Stock Looks Like A Bargain After A 396% Run

Simply Wall St.
·
Aug 23

Market Chatter: Hims & Hers Health Faces Nearly $75,000 Bill From Card Disputes

MT Newswires Live
·
Aug 22

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live
·
Aug 22

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 22

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Dow Jones
·
Aug 22

Scholar Rock price target raised to $64 from $58 at Wedbush

TIPRANKS
·
Aug 21

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

TIPRANKS
·
Aug 21

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS
·
Aug 21